{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:20:19Z","timestamp":1790882419402,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,11,13]],"date-time":"2009-11-13T00:00:00Z","timestamp":1258070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Vitamin D deficiency has potential roles in breast cancer etiology and progression. Vitamin D deficiency has also been associated with increased toxicity from bisphosphonate therapy. The optimal dose of vitamin D supplementation is unknown, but daily sunlight exposure can generate the equivalent of a 10,000\u2010IU oral dose of vitamin D<jats:sub>3<\/jats:sub>. This study therefore aimed to assess the effect of this dose of vitamin D<jats:sub>3<\/jats:sub> in patients with bone metastases from breast cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients with bone metastases treated with bisphosphonates were enrolled into this single\u2010arm phase 2 study. Patients received 10,000 IU of vitamin D<jats:sub>3<\/jats:sub> and 1000 mg of calcium supplementation each day for 4 months. The effect of this treatment on palliation, bone resorption markers, calcium metabolism, and toxicity were evaluated at baseline and monthly thereafter.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Forty patients were enrolled. No significant changes in bone resorption markers were seen. Despite no change in global pain scales, there was a significant reduction in the number of sites of pain. A small but statistically significant increase in serum calcium was seen, as was a significant decrease in serum parathyroid hormone. Treatment unmasked 2 cases of primary hyperparathyroidism, but was not associated with direct toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Daily doses of 10,000 IU vitamin D<jats:sub>3<\/jats:sub> for 4 months appear safe in patients without comorbid conditions causing hypersensitivity to vitamin D. Treatment reduced inappropriately elevated parathyroid hormone levels, presumably caused by long\u2010term bisphosphonate use. There did not appear to be a significant palliative benefit nor any significant change in bone resorption. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24749","type":"journal-article","created":{"date-parts":[[2009,11,13]],"date-time":"2009-11-13T15:23:05Z","timestamp":1258125785000},"page":"284-291","source":"Crossref","is-referenced-by-count":61,"title":["A phase 2 trial exploring the effects of high\u2010dose (10,000 IU\/day) vitamin D<sub>3<\/sub> in breast cancer patients with bone metastases"],"prefix":"10.1002","volume":"116","author":[{"given":"Eitan","family":"Amir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit C.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dranitsaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E. C.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Vieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei S.","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,13]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(86)90085-3"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(96)00048-9"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90405-8"},{"key":"e_1_2_7_5_2","first-page":"1653","article-title":"1 alpha,25\u2010Dihydroxy\u201016\u2010ene\u201023\u2010yne\u201026,27\u2010hexafluorocholecalciferol (Ro24\u20105531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat","volume":"54","author":"Anzano MA","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-7435(90)90058-R"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/19.4.820"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.042747"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0725"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2008.06.002"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn360"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.2.524"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042092"},{"key":"e_1_2_7_14_2","first-page":"2707","article-title":"Altered calcium metabolism in patients on long\u2010term bisphosphonate therapy for metastatic breast cancer","volume":"29","author":"Simmons C","year":"2009","journal-title":"Anticancer Res."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7458.156"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1079\/PNS19750022"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0630461"},{"key":"e_1_2_7_18_2","doi-asserted-by":"crossref","first-page":"638S","DOI":"10.1093\/ajcn\/61.3.638S","article-title":"Environmental factors that influence the cutaneous production of vitamin D","volume":"61","author":"Holick MF","year":"1995","journal-title":"Am J Clin Nutr."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1998.13.8.1238"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/85.1.6"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.30.2.144"},{"key":"e_1_2_7_22_2","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland CS","year":"1994","journal-title":"Ann Acad Med Singapore."},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2008.08.005"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.10.1789"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067312"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90483-M"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.03.007"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.16.1730"},{"key":"e_1_2_7_30_2","volume-title":"Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride","author":"Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine","year":"1997"},{"key":"e_1_2_7_31_2","volume-title":"Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin D","author":"Health and Consumer Protection Directorate\u2010General","year":"2002"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/86.3.645"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00277-9"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.091"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9212"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9583-y"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90245-7"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03343867"},{"key":"e_1_2_7_39_2","first-page":"1043","article-title":"Relevance of vitamin D metabolite concentrations in supporting the diagnosis of primary hyperparathyroidism","volume":"110","author":"Vieth R","year":"1991","journal-title":"Surgery."},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-3-199708010-00004"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-9167-2_51"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24749","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:15:13Z","timestamp":1760296513000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,13]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,1,15]]}},"alternative-id":["10.1002\/cncr.24749"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24749","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,13]]}}}